Guardant360 identifies patients with advanced colorectal cancer eligible for FDA-approved matched therapy

Guardant360 provides complete genotyping of your colorectal cancer patients for guideline-recommended biomarkers, including MSI, expanded KRAS/NRAS, and BRAF

<table>
<thead>
<tr>
<th>MSI</th>
<th>KRAS</th>
<th>NRAS</th>
<th>BRAF</th>
<th>NTRK1</th>
<th>ERBB2</th>
</tr>
</thead>
<tbody>
<tr>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

Recent study shows advanced colon cancer patients may get the wrong therapy due to incomplete testing\(^1\)

72% of patients who received anti-EGFR therapy did not have guideline-aligned RAS and BRAF testing to determine eligibility for that treatment

Only 40% of patients received guideline-recommended testing needed to determine optimal therapy

Unparalleled Clinical Validation

Proven high sensitivity across multiple solid tumors, including CRC

<table>
<thead>
<tr>
<th>SOMATIC ALTERATION DETECTION RATE [%]</th>
<th>0</th>
<th>20</th>
<th>40</th>
<th>60</th>
<th>80</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRC</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>NSCLC</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Prostate</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Breast</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

150+ peer-reviewed studies including:

6 validation studies in CRC\(^3-8\)

3 outcomes studies in CRC\(^9-11\)

- Response rates to therapy selected based on Guardant360 results are consistent with tissue-based studies
- High concordance with tissue-based tests in multiple studies
Clinical presentation

• 63-year-old male, referred to a large cancer center after metastases appeared

Testing

• No previous genomic testing was recorded for the patient
• Oncologist ordered Guardant360 to receive guideline-recommended results within 7 days while locating archival tissue sample
• Guardant360 found a KRAS exon 4 mutation

Treatment

• Oncologist excluded anti-EGFR therapy from the patient’s treatment plan
• The patient was put on FOLFOX + anti-VEGF therapy (AVASTIN®) and has had a strong response for more than 6 months

Example patient type that benefits from Guardant360

Advanced colorectal cancer patient who was not tested for KRAS, NRAS, BRAF, and/or MSI

Why use Guardant360 for guideline-complete testing

• Covered by Medicare for all patients with advanced cancer across solid tumors*
• Take back control of your patients’ genomic testing with a simple blood draw
• Fast, reliable results in 7 days

*Excluding central nervous system tumors